<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00544219</url>
  </required_header>
  <id_info>
    <org_study_id>SAKK 38/07</org_study_id>
    <secondary_id>SWS-SAKK-38-07</secondary_id>
    <secondary_id>EU-20763</secondary_id>
    <secondary_id>EUDRACT-2007-001806-26</secondary_id>
    <secondary_id>CDR0000569869</secondary_id>
    <nct_id>NCT00544219</nct_id>
  </id_info>
  <brief_title>PET Scans in Patients With Diffuse Large B-Cell Lymphoma Receiving Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone</brief_title>
  <official_title>Prospective Evaluation of the Predictive Value of PET in Patients With Diffuse Large B-cell-lymphoma Under R-CHOP-14. A Multicenter Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Swiss Group for Clinical Cancer Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Swiss Group for Clinical Cancer Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Studying PET scans given to patients with cancer who are undergoing treatment may
      help doctors predict how patients will respond to treatment.

      PURPOSE: This clinical trial is studying PET scans in patients with diffuse large B-cell
      lymphoma who are receiving rituximab together with cyclophosphamide, doxorubicin,
      vincristine, and prednisone.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  To evaluate if an early positive positron emission tomography (PET) scan after 2 courses
           of rituximab with cyclophosphamide, doxorubicin hydrochloride, vincristine, and
           prednisone can be used to identify a group of patients having a poor prognosis.

      Secondary

        -  To compare modified PET/CT scan response criteria with revised standard response
           criteria.

        -  To evaluate, in a prospective manner, whether a proliferation-inducing ligand (APRIL)
           expression is a prognostic factor in patients treated with this regimen.

      OUTLINE: This is a multicenter study.

      Patients receive rituximab IV, cyclophosphamide IV, doxorubicin hydrochloride IV, and
      vincristine IV on day 1 and oral prednisone on days 1-5. Treatment repeats every 14 days for
      up to 6 courses in the absence of disease progression or unacceptable toxicity. Rituximab IV
      alone is continued for an additional 2 courses after completion of the initial 6 courses.

      Patients undergo positron emission tomography (PET) scan prior to and after completion of
      study therapy. Patients also undergo PET scan after course 2, and those with a positive PET
      result undergo an additional PET scan after course 4.

      Previously collected tumor samples are analyzed for a proliferation-inducing ligand (APRIL)
      expression.

      After completion of study treatment, patients are followed periodically for up to 5 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Event-free survival</measure>
    <time_frame>at 2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Event-free survival</measure>
    <time_frame>at 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival during follow-up</measure>
    <time_frame>at 2 and 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response</measure>
    <time_frame>at 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positron emission tomography (PET) results</measure>
    <time_frame>at 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Histological results of remaining PET-positive lesion(s) after treatment</measure>
    <time_frame>at 2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">156</enrollment>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>R-Chop 14</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Standard treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rituximab</intervention_name>
    <description>375 mg/m2 i.v. per cycle</description>
    <arm_group_label>R-Chop 14</arm_group_label>
    <other_name>Mabthera</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <description>750 mg/m2 i.v. per cycle</description>
    <arm_group_label>R-Chop 14</arm_group_label>
    <other_name>Endoxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin hydrochloride</intervention_name>
    <description>50 mg/m2 i.v. per cycle</description>
    <arm_group_label>R-Chop 14</arm_group_label>
    <other_name>Adriamycin, Adriblastin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prednisone</intervention_name>
    <description>100 mg/day p.o. per cycle</description>
    <arm_group_label>R-Chop 14</arm_group_label>
    <other_name>Deltasone, Orasone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vincristine sulfate</intervention_name>
    <description>1.4 mg/m2 (max. 2.0 mg) i.v. per cycle</description>
    <arm_group_label>R-Chop 14</arm_group_label>
    <other_name>Oncovin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>positron emission tomography</intervention_name>
    <description>PET Scan during treatment</description>
    <arm_group_label>R-Chop 14</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

        Inclusion criteria:

          -  Histologically confirmed diagnosis of CD20+ diffuse large B-cell lymphoma (DLBCL)

               -  Stage I-IV disease

               -  All IPI risk groups

          -  Must be positron emission tomography (PET)-positive

          -  At least one measurable lesion ≥ 15 mm in its shortest axis (greatest transverse
             diameter) for jugulodigastric and infra-carinal lymph nodes with CT scan (MRI is
             allowed only if CT scan cannot be performed)

               -  Otherwise the shortest axis (greatest transverse diameter) must be ≥ 10 mm

               -  Lesions should be selected according to the following features:

                    -  Clearly measurable in two perpendicular dimensions

                    -  From as disparate regions of the body as possible

                    -  Include mediastinal and retroperitoneal areas of disease whenever these
                       sites are involved

        Exclusion criteria:

          -  Secondary DLBCL (in transformation)

          -  Evidence of symptomatic CNS disease

        PATIENT CHARACTERISTICS:

        Inclusion criteria:

          -  ECOG or WHO performance status 0-2

          -  Cardiac ejection fraction ≥ 50% as assessed by echocardiography

          -  Sufficient hematological values, hepatic and renal function

          -  Patient condition, compliance, and geographic proximity must allow proper staging and
             completion of treatment and follow-up

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception during and for 12 months after
             completion of study therapy

        Exclusion criteria:

          -  Prior or concurrent hematological malignancies

               -  Patients who have had prior solid organ tumors that required no treatment over
                  the past 5 years and are currently disease-free are allowed

          -  Unstable cardiac disease within the past 6 months

          -  Any serious underlying medical condition (at the judgment of the investigator) that
             could impair the ability of the patient to participate in the study (e.g., active
             autoimmune disease, uncontrolled diabetes, HIV- and hepatitis-infection)

          -  Known hypersensitivity to any component of the study drugs

        PRIOR CONCURRENT THERAPY:

        Exclusion criteria:

          -  Prior chemotherapy, radiotherapy, or immunotherapy (e.g., rituximab) for lymphoma

          -  Prior anthracycline treatment

          -  Concurrent radiotherapy

          -  Concurrent regular corticosteroids in the past 4 weeks

               -  Doses ≤ 20 mg/day of prednisone for indications other than lymphoma or
                  lymphoma-related symptoms allowed

          -  Concurrent drugs contraindicated for use with the study drugs according to the
             Swissmedic-approved product information

          -  Other concurrent experimental drugs or other anticancer therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christoph Mamot, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Kantonsspital Aarau</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mario Bargetzi, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Kantonsspital Aarau</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Giovanni Martinelli, MD</last_name>
    <role>Study Chair</role>
    <affiliation>European Institute of Oncology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>European Institute of Oncology</name>
      <address>
        <city>Milan</city>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hirslanden Klinik Aarau</name>
      <address>
        <city>Aarau</city>
        <zip>CH-5001</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonspital Aarau</name>
      <address>
        <city>Aarau</city>
        <zip>CH-5001</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Baden</name>
      <address>
        <city>Baden</city>
        <zip>CH-5404</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Streit</name>
      <address>
        <city>Baden</city>
        <zip>CH-5404</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Claraspital AG</name>
      <address>
        <city>Basel</city>
        <zip>CH-4016</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsspital-Basel</name>
      <address>
        <city>Basel</city>
        <zip>CH-4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncology Institute of Southern Switzerland</name>
      <address>
        <city>Bellinzona</city>
        <zip>CH-6500</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inselspital Bern</name>
      <address>
        <city>Bern</city>
        <zip>CH-3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Bruderholz</name>
      <address>
        <city>Bruderholz</city>
        <zip>CH-4101</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Graubuenden</name>
      <address>
        <city>Chur</city>
        <zip>CH-7000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Cantonal Universitaire de Geneve</name>
      <address>
        <city>Geneva</city>
        <zip>CH-1211</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Liestal</name>
      <address>
        <city>Liestal</city>
        <zip>CH-4410</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Olten</name>
      <address>
        <city>Olten</city>
        <zip>CH-4600</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Beretta</name>
      <address>
        <city>Rheinfelden</city>
        <zip>CH-4310</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital - St. Gallen</name>
      <address>
        <city>St. Gallen</city>
        <zip>CH-9007</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regionalspital</name>
      <address>
        <city>Thun</city>
        <zip>3600</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Winterthur</name>
      <address>
        <city>Winterthur</city>
        <zip>CH-8400</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UniversitaetsSpital Zuerich</name>
      <address>
        <city>Zurich</city>
        <zip>CH-8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 13, 2007</study_first_submitted>
  <study_first_submitted_qc>October 13, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 16, 2007</study_first_posted>
  <last_update_submitted>June 14, 2016</last_update_submitted>
  <last_update_submitted_qc>June 14, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 15, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>contiguous stage II adult diffuse large cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
  <keyword>stage I adult diffuse large cell lymphoma</keyword>
  <keyword>stage III adult diffuse large cell lymphoma</keyword>
  <keyword>stage IV adult diffuse large cell lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Vincristine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

